Entering text into the input field will update the search result below

Salix settles Zegerid patent infringement suit

Sep. 22, 2014 8:32 AM ETSalix Pharmaceuticals, Ltd. (SLXP) StockSNTS, SLXPBy: Douglas W. House, SA News Editor
  • Salix Pharmaceuticals (NASDAQ:SLXP) settles its patent infringement case with Par Pharmaceutical, Inc. over Zegerid (omeprazole). Salix owns the licenses by virtue of its acquisition of Santarus Pharmaceuticals (NASDAQ:SNTS) last November. Santarus exclusively licensed the patents from the University of Missouri.
  • Under the terms of the settlement agreement, Par agrees not to challenge the validity of the patents in the future and agrees not to sell generic versions of Zegerid during the terms of the patents. It will make a one-time payment of $100M to an escrow account that will be allocated between Santarus and the University of Missouri pursuant to their 2001 Exclusive License Agreement.

Recommended For You

More Trending News

Related Stocks

SymbolLast Price% Chg
SLXP--
Salix Pharmaceuticals, Ltd.
To ensure this doesn’t happen in the future, please enable Javascript and cookies in your browser.
Is this happening to you frequently? Please report it on our feedback forum.
If you have an ad-blocker enabled you may be blocked from proceeding. Please disable your ad-blocker and refresh.